The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust collaborated to solve global health concerns using science and technology.
Tags: Novo Nordisk
Ozempic, Wegovy Users May Face Rare Blindness Risk, Study Suggests Further Investigation Needed
A new study published in JAMA Ophthalmology suggests that taking Ozempic or Wegovy may increase the risk of developing a rare form of blindness.
Joe Biden, Bernie Sanders Urge Novo Nordisk and Eli Lilly to Lower Prices of Weight Loss Drugs
President Joe Biden and Senator Bernie Sanders have urged Novo Nordisk and Eli Lilly to lower the prices of their popular weight loss drugs.
Novo Nordisk Announces $4.1 Billion Investment in North Carolina for Wegovy and Ozempic Production Boost
Novo Nordisk announced a $4.1 billion investment to build a new manufacturing plant in Clayton, North Carolina, to increase production capacity for its popular drugs Wegovy, Ozempic, and other injectable therapies.
Novo Nordisk CEO to Testify Before Senate After Sanders' Subpoena Threat Over Drug Pricing
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate following Sen. Bernie Sanders' threat to subpoena the company over the pricing of diabetes drug Ozempic and obesity drug Wegovy.
Latest News
Novo Nordisk exceeded profit expectations in Q1 2024 with a 28% surge in net profit, driven by Wegovy's success.
A recent study suggests that Novo Nordisk's diabetes drug, Ozempic, priced at nearly $1,000 in the US, could be produced for less than $5 a month.
The successful weight loss trial of the amycretin pill pushed Novo Nordisk past Tesla in market value to $604 billion, increasing investor interest in innovative solutions for major health issues like obesity.
Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.
Novo AS invests in Ophhtotech Corporation for the further development of drug Fovista. In an announcement made today, Ophthotech Corporation said it was able to raise US$175 million in funding to finance the global Phase 3 clinical program of its lead medication Fovista.
